10 February 2026
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Shayne Kennedy Lead | Latham & Watkins LLP | Partner | Capital Markets | Orange County/Bay Area |
| Ross McAloon Lead | Latham & Watkins LLP | Partner | Capital Markets | Orange County/Bay Area |
| Omeed Valipour | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Sterling Swift | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
| Ariana Alemi | Latham & Watkins LLP | Associate | Capital Markets | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 150m (US$150 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- SpyGlass Pharma, Inc. (Issuer)